BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Figueroa I, Johnson S, Sambol SP, Goldstein EJ, Citron DM, Gerding DN. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin Infect Dis. 2012;55 Suppl 2:S104-S109. [PMID: 22752857 DOI: 10.1093/cid/cis357] [Cited by in Crossref: 98] [Cited by in F6Publishing: 87] [Article Influence: 9.8] [Reference Citation Analysis]
Number Citing Articles
1 Gebhart D, Lok S, Clare S, Tomas M, Stares M, Scholl D, Donskey CJ, Lawley TD, Govoni GR. A modified R-type bacteriocin specifically targeting Clostridium difficile prevents colonization of mice without affecting gut microbiota diversity. MBio. 2015;6:pii: e02368-14. [PMID: 25805733 DOI: 10.1128/mbio.02368-14] [Cited by in Crossref: 64] [Cited by in F6Publishing: 40] [Article Influence: 9.1] [Reference Citation Analysis]
2 Staley C, Halaweish H, Graiziger C, Hamilton MJ, Kabage AJ, Galdys AL, Vaughn BP, Vantanasiri K, Suryanarayanan R, Sadowsky MJ, Khoruts A. Lower endoscopic delivery of freeze-dried intestinal microbiota results in more rapid and efficient engraftment than oral administration. Sci Rep 2021;11:4519. [PMID: 33633264 DOI: 10.1038/s41598-021-84152-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Varier RU, Biltaji E, Smith KJ, Roberts MS, Jensen MK, LaFleur J, Nelson RE. Cost-effectiveness analysis of treatment strategies for initial Clostridium difficile infection. Clin Microbiol Infect 2014;20:1343-51. [PMID: 25366338 DOI: 10.1111/1469-0691.12805] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
4 Rahmoun LA, Azrad M, Peretz A. Antibiotic Resistance and Biofilm Production Capacity in Clostridioides difficile. Front Cell Infect Microbiol 2021;11:683464. [PMID: 34422678 DOI: 10.3389/fcimb.2021.683464] [Reference Citation Analysis]
5 Amadou Amani S, Shadid T, Ballard JD, Lang ML. Clostridioides difficile Infection Induces an Inferior IgG Response to That Induced by Immunization and Is Associated with a Lack of T Follicular Helper Cell and Memory B Cell Expansion. Infect Immun 2020;88:e00829-19. [PMID: 31871095 DOI: 10.1128/IAI.00829-19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Thomas E, Bémer P, Eckert C, Guillouzouic A, Orain J, Corvec S, Caillon J, Bourigault C, Boutoille D. Clostridium difficile infections: analysis of recurrence in an area with low prevalence of 027 strain. Journal of Hospital Infection 2016;93:109-12. [DOI: 10.1016/j.jhin.2016.01.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
7 El Hage R, Hernandez-Sanabria E, Van de Wiele T. Emerging Trends in "Smart Probiotics": Functional Consideration for the Development of Novel Health and Industrial Applications. Front Microbiol 2017;8:1889. [PMID: 29033923 DOI: 10.3389/fmicb.2017.01889] [Cited by in Crossref: 69] [Cited by in F6Publishing: 49] [Article Influence: 13.8] [Reference Citation Analysis]
8 Cole SA, Stahl TJ. Persistent and Recurrent Clostridium difficile Colitis. Clin Colon Rectal Surg 2015;28:65-9. [PMID: 26034401 DOI: 10.1055/s-0035-1547333] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
9 Chilton CH, Crowther GS, Ashwin H, Longshaw CM, Wilcox MH. Association of Fidaxomicin with C. difficile Spores: Effects of Persistence on Subsequent Spore Recovery, Outgrowth and Toxin Production. PLoS One 2016;11:e0161200. [PMID: 27556739 DOI: 10.1371/journal.pone.0161200] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
10 Seekatz AM, Wolfrum E, DeWald CM, Putler RKB, Vendrov KC, Rao K, Young VB. Presence of multiple Clostridium difficile strains at primary infection is associated with development of recurrent disease. Anaerobe 2018;53:74-81. [PMID: 29859301 DOI: 10.1016/j.anaerobe.2018.05.017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
11 Blanco N, Foxman B, Malani AN, Zhang M, Walk S, Rickard AH, Eisenberg MC. An in silico evaluation of treatment regimens for recurrent Clostridium difficile infection. PLoS One 2017;12:e0182815. [PMID: 28800598 DOI: 10.1371/journal.pone.0182815] [Reference Citation Analysis]
12 Genth H, Just I. Large clostridial glycosylating toxins modifying small GTPases. The Comprehensive Sourcebook of Bacterial Protein Toxins. Elsevier; 2015. pp. 441-62. [DOI: 10.1016/b978-0-12-800188-2.00016-1] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
13 Crowther GS, Chilton CH, Todhunter SL, Nicholson S, Freeman J, Wilcox MH. Recurrence of dual-strain Clostridium difficile infection in an in vitro human gut model. J Antimicrob Chemother 2015;70:2316-21. [DOI: 10.1093/jac/dkv108] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
14 Ross CL, Spinler JK, Savidge TC. Structural and functional changes within the gut microbiota and susceptibility to Clostridium difficile infection. Anaerobe 2016;41:37-43. [PMID: 27180006 DOI: 10.1016/j.anaerobe.2016.05.006] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
15 Islam J, Cheek E, Navani V, Rajkumar C, Cohen J, Llewelyn MJ. Influence of cohorting patients with Clostridium difficile infection on risk of symptomatic recurrence. J Hosp Infect 2013;85:17-21. [PMID: 23910403 DOI: 10.1016/j.jhin.2013.06.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
16 Haran JP, Bradley E, Howe E, Wu X, Tjia J. Medication Exposure and Risk of Recurrent Clostridium difficile Infection in Community-Dwelling Older People and Nursing Home Residents. J Am Geriatr Soc 2018;66:333-8. [DOI: 10.1111/jgs.15176] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Hargreaves KR, Colvin HV, Patel KV, Clokie JJ, Clokie MR. Genetically diverse Clostridium difficile strains harboring abundant prophages in an estuarine environment. Appl Environ Microbiol 2013;79:6236-43. [PMID: 23913427 DOI: 10.1128/AEM.01849-13] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
18 D'agostino RB, Collins SH, Pencina KM, Kean Y, Gorbach S. Risk Estimation for Recurrent Clostridium difficile Infection Based on Clinical Factors. Clinical Infectious Diseases 2014;58:1386-93. [DOI: 10.1093/cid/ciu107] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 5.5] [Reference Citation Analysis]
19 Redding LE, Kelly BJ, Stefanovski D, Lautenbach JK, Tolomeo P, Cressman L, Gruber E, Meily P, Lautenbach E. Pet Ownership Protects Against Recurrence of Clostridioides difficile Infection. Open Forum Infect Dis 2020;7:ofz541. [PMID: 31976354 DOI: 10.1093/ofid/ofz541] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Stanley JD, Bartlett JG, Dart BW 4th, Ashcraft JH. Clostridium difficile infection. Curr Probl Surg 2013;50:302-37. [PMID: 23764494 DOI: 10.1067/j.cpsurg.2013.02.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
21 Budi N, Safdar N, Rose WE. Treatment issues in recurrent Clostridioides difficile infections and the possible role of germinants. FEMS Microbes 2020;1:xtaa001. [DOI: 10.1093/femsmc/xtaa001] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Johanesen PA, Mackin KE, Hutton ML, Awad MM, Larcombe S, Amy JM, Lyras D. Disruption of the Gut Microbiome: Clostridium difficile Infection and the Threat of Antibiotic Resistance. Genes (Basel) 2015;6:1347-60. [PMID: 26703737 DOI: 10.3390/genes6041347] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 7.6] [Reference Citation Analysis]
23 Merrigan MM, Venugopal A, Roxas JL, Anwar F, Mallozzi MJ, Roxas BA, Gerding DN, Viswanathan VK, Vedantam G. Surface-layer protein A (SlpA) is a major contributor to host-cell adherence of Clostridium difficile. PLoS One 2013;8:e78404. [PMID: 24265687 DOI: 10.1371/journal.pone.0078404] [Cited by in Crossref: 66] [Cited by in F6Publishing: 68] [Article Influence: 7.3] [Reference Citation Analysis]
24 Collins J, Auchtung JM. Control of Clostridium difficile Infection by Defined Microbial Communities. Microbiol Spectr 2017;5. [PMID: 28936948 DOI: 10.1128/microbiolspec.BAD-0009-2016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
25 Durovic A, Widmer AF, Frei R, Tschudin-Sutter S. Distinguishing Clostridium difficile Recurrence From Reinfection: Independent Validation of Current Recommendations. Infect Control Hosp Epidemiol 2017;38:891-6. [PMID: 28592348 DOI: 10.1017/ice.2017.119] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
26 . Hygienemaßnahmen bei Clostridioides difficile-Infektion (CDI): Empfehlung der Kommission für Krankenhaushygiene und Infektionsprävention (KRINKO) beim Robert Koch-Institut. Bundesgesundheitsbl 2019;62:906-23. [DOI: 10.1007/s00103-019-02959-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
27 Eyre DW, Babakhani F, Griffiths D, Seddon J, Del Ojo Elias C, Gorbach SL, Peto TE, Crook DW, Walker AS. Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile. J Infect Dis 2014;209:1446-51. [PMID: 24218500 DOI: 10.1093/infdis/jit598] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 4.2] [Reference Citation Analysis]
28 Zeng Z, Zhao H, Dorr MB, Shen J, Wilcox MH, Poxton IR, Guris D, Li J, Shaw PM. Bezlotoxumab for prevention of Clostridium difficile infection recurrence: Distinguishing relapse from reinfection with whole genome sequencing. Anaerobe 2020;61:102137. [DOI: 10.1016/j.anaerobe.2019.102137] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Rao K, Young VB, Aronoff DM. Fecal microbiota therapy: ready for prime time? Infect Control Hosp Epidemiol 2014;35:28-30. [PMID: 24334795 DOI: 10.1086/674395] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
30 Trindade C, Domingues RMC, Ferreira E. The epidemiology of Clostridioides difficile infection in Brazil: A systematic review covering thirty years. Anaerobe 2019;58:13-21. [DOI: 10.1016/j.anaerobe.2019.03.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
31 van Prehn J, Reigadas E, Vogelzang EH, Bouza E, Hristea A, Guery B, Krutova M, Norén T, Allerberger F, Coia J, Goorhuis A, van Rossen TM, Ooijevaar RE, Burns K, Scharvik Olesen BR, Tschudin-Sutter S, Wilcox MH, Vehreschild M, Fitzpatrick F, Kuijper EJ; guideline committee of the European Study Group on Clostridioides difficile. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect 2021:S1198-743X(21)00568-1. [PMID: 34678515 DOI: 10.1016/j.cmi.2021.09.038] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Dayananda P, Wilcox MH. A Review of Mixed Strain Clostridium difficile Colonization and Infection. Front Microbiol 2019;10:692. [PMID: 31024483 DOI: 10.3389/fmicb.2019.00692] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
33 Jazmati N, Hain O, Hellmich M, Plum G, Kaasch A. PCR based detection of tcdCΔ117 in Clostridium difficile infection identifies patients at risk for recurrence - A hospital-based prospective observational study. Anaerobe 2019;57:39-44. [PMID: 30878603 DOI: 10.1016/j.anaerobe.2019.03.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
34 Dubois T, Tremblay YDN, Hamiot A, Martin-Verstraete I, Deschamps J, Monot M, Briandet R, Dupuy B. A microbiota-generated bile salt induces biofilm formation in Clostridium difficile. NPJ Biofilms Microbiomes 2019;5:14. [PMID: 31098293 DOI: 10.1038/s41522-019-0087-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 10.7] [Reference Citation Analysis]
35 Du C, Luo Y, Walsh S, Grinspan A. Oral Fecal Microbiota Transplant Capsules Are Safe and Effective for Recurrent Clostridioides difficile Infection: A Systematic Review and Meta-Analysis. J Clin Gastroenterol 2021;55:300-8. [PMID: 33471490 DOI: 10.1097/MCG.0000000000001495] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
36 Wong SH, Ip M, Hawkey PM, Lo N, Hardy K, Manzoor S, Hui WW, Choi KW, Wong RY, Yung IM, Cheung CS, Lam KL, Kwong T, Wu WK, Ng SC, Wu JC, Sung JJ, Lee N. High morbidity and mortality of Clostridium difficile infection and its associations with ribotype 002 in Hong Kong. J Infect 2016;73:115-22. [PMID: 27246801 DOI: 10.1016/j.jinf.2016.05.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
37 Debast SB, Bauer MP, Kuijper EJ;  European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20 Suppl 2:1-26. [PMID: 24118601 DOI: 10.1111/1469-0691.12418] [Cited by in Crossref: 692] [Cited by in F6Publishing: 607] [Article Influence: 86.5] [Reference Citation Analysis]
38 Watt M, Dinh A, Le Monnier A, Tilleul P. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France. Journal of Medical Economics 2017;20:678-86. [DOI: 10.1080/13696998.2017.1302946] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
39 Johnson S, Citron DM, Gerding DN, Wilcox MH, Goldstein EJC, Sambol SP, Best EL, Eves K, Jansen E, Dorr MB. Efficacy of bezlotoxumab in trial participants infected with Clostridioides difficile strain BI associated with poor outcomes. Clin Infect Dis 2020:ciaa1035. [PMID: 32735653 DOI: 10.1093/cid/ciaa1035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
40 Rao K, Young VB. Fecal microbiota transplantation for the management of Clostridium difficile infection. Infect Dis Clin North Am 2015;29:109-22. [PMID: 25677705 DOI: 10.1016/j.idc.2014.11.009] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 7.0] [Reference Citation Analysis]
41 Nana T, Moore C, Boyles T, Brink AJ, Cleghorn J, Devenish LM, du Toit B, Fredericks ES, Lekalakala-Mokaba MR, Maluleka C, Rajabally MN, Reubenson G, Shuping L, Swart K, Swe Han KS, Wadula J, Wojno J, Lowman W. South African Society of Clinical Microbiology Clostridioides difficile infection diagnosis, management and infection prevention and control guideline. S Afr J Infect Dis 2020;35:219. [PMID: 34485483 DOI: 10.4102/sajid.v35i1.219] [Reference Citation Analysis]
42 Durham DP, Olsen MA, Dubberke ER, Galvani AP, Townsend JP. Quantifying Transmission of Clostridium difficile within and outside Healthcare Settings. Emerg Infect Dis 2016;22:608-16. [PMID: 26982504 DOI: 10.3201/eid2204.150455] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
43 Tijerina-Rodríguez L, Villarreal-Treviño L, Baines SD, Morfín-Otero R, Camacho-Ortíz A, Flores-Treviño S, Maldonado-Garza H, Rodríguez-Noriega E, Garza-González E. High sporulation and overexpression of virulence factors in biofilms and reduced susceptibility to vancomycin and linezolid in recurrent Clostridium [Clostridioides] difficile infection isolates. PLoS One 2019;14:e0220671. [PMID: 31365590 DOI: 10.1371/journal.pone.0220671] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
44 Chilton C, Pickering D, Freeman J. Microbiologic factors affecting Clostridium difficile recurrence. Clinical Microbiology and Infection 2018;24:476-82. [DOI: 10.1016/j.cmi.2017.11.017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
45 Spencer J, Leuzzi R, Buckley A, Irvine J, Candlish D, Scarselli M, Douce GR. Vaccination against Clostridium difficile using toxin fragments: Observations and analysis in animal models. Gut Microbes 2014;5:225-32. [PMID: 24637800 DOI: 10.4161/gmic.27712] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
46 Piktel E, Pogoda K, Savage PB, Bucki R. The search for new sporicidal agents for medical use: where are we? Future Microbiol 2017;12:735-7. [PMID: 28593804 DOI: 10.2217/fmb-2017-0069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
47 Theriot CM, Bowman AA, Young VB. Antibiotic-Induced Alterations of the Gut Microbiota Alter Secondary Bile Acid Production and Allow for Clostridium difficile Spore Germination and Outgrowth in the Large Intestine. mSphere 2016;1:e00045-15. [PMID: 27239562 DOI: 10.1128/mSphere.00045-15] [Cited by in Crossref: 184] [Cited by in F6Publishing: 144] [Article Influence: 30.7] [Reference Citation Analysis]
48 Mileto S, Das A, Lyras D, Fischetti VA, Novick RP, Ferretti JJ, Portnoy DA, Rood JI. Enterotoxic Clostridia: Clostridioides difficile Infections. Microbiol Spectr 2019;7. [DOI: 10.1128/microbiolspec.gpp3-0015-2018] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
49 Singh T, Bedi P, Bumrah K, Singh J, Rai M, Seelam S. Updates in Treatment of Recurrent Clostridium difficile Infection. J Clin Med Res. 2019;11:465-471. [PMID: 31236163 DOI: 10.14740/jocmr3854] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
50 Yokoyama Y, Shiota A, Asai N, Koizumi Y, Yamagishi Y, Sakanashi D, Nakamura A, Suematsu H, Ohnishi M, Mikamo H. Risk factors of first recurrence of Clostridioides difficile infection. Anaerobe 2022;:102556. [PMID: 35395406 DOI: 10.1016/j.anaerobe.2022.102556] [Reference Citation Analysis]
51 Scott LJ. Fidaxomicin: A Review of Its Use in Patients with Clostridium difficile Infection. Drugs 2013;73:1733-47. [DOI: 10.1007/s40265-013-0134-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
52 Gupta SB, Dubberke ER. Overview and changing epidemiology of Clostridium difficile infection. Seminars in Colon and Rectal Surgery 2014;25:118-23. [DOI: 10.1053/j.scrs.2014.05.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
53 McLure A, Clements ACA, Kirk M, Glass K. Healthcare-Associated Clostridium difficile Infections are Sustained by Disease from the Community. Bull Math Biol 2017;79:2242-57. [PMID: 28776206 DOI: 10.1007/s11538-017-0328-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
54 Miller-Roll T, Na'amnih W, Cohen D, Carmeli Y, Adler A. Molecular types and antimicrobial susceptibility patterns of Clostridium difficile isolates in different epidemiological settings in a tertiary care center in Israel. Diagn Microbiol Infect Dis 2016;86:450-4. [PMID: 27638350 DOI: 10.1016/j.diagmicrobio.2016.08.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
55 Lawley TD, Young VB. Murine models to study Clostridium difficile infection and transmission. Anaerobe 2013;24:94-7. [PMID: 24076318 DOI: 10.1016/j.anaerobe.2013.09.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
56 Loo VG, Davis I, Embil J, Evans GA, Hota S, Lee C, Lee TC, Longtin Y, Louie T, Moayyedi P, Poutanen S, Simor AE, Steiner T, Thampi N, Valiquette L. Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for Clostridium difficile infection. Official Journal of the Association of Medical Microbiology and Infectious Disease Canada 2018;3:71-92. [DOI: 10.3138/jammi.2018.02.13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Umemura T, Ota A, Mutoh Y, Norizuki C, Mizuno T, Kozaki K, Ikeda Y, Ichihara T. Efficacy of prolonged tapered and pulsed vancomycin regimen on recurrent Clostridioides difficile infection in the Japanese setting: a case control study. J Pharm Health Care Sci 2019;5:19. [PMID: 31410293 DOI: 10.1186/s40780-019-0147-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
58 Gerding DN, Lessa FC. The epidemiology of Clostridium difficile infection inside and outside health care institutions. Infect Dis Clin North Am 2015;29:37-50. [PMID: 25582647 DOI: 10.1016/j.idc.2014.11.004] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 7.4] [Reference Citation Analysis]
59 Larrainzar-Coghen T, Rodriguez-Pardo D, Puig-Asensio M, Rodríguez V, Ferrer C, Bartolomé R, Pigrau C, Fernández-Hidalgo N, Pumarola T, Almirante B. First recurrence of Clostridium difficile infection: clinical relevance, risk factors, and prognosis. Eur J Clin Microbiol Infect Dis 2016;35:371-8. [PMID: 26753991 DOI: 10.1007/s10096-015-2549-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
60 Luo Y, Tixier EN, Grinspan AM. Fecal Microbiota Transplantation for Clostridioides difficile in High-Risk Older Adults Is Associated with Early Recurrence. Dig Dis Sci 2020;65:3647-51. [PMID: 32078714 DOI: 10.1007/s10620-020-06147-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
61 Goldstein EJC, Johnson SJ, Maziade PJ, Evans CT, Sniffen JC, Millette M, McFarland LV. Probiotics and prevention of Clostridium difficile infection. Anaerobe 2017;45:114-9. [PMID: 27988389 DOI: 10.1016/j.anaerobe.2016.12.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
62 Marsh JW, Curry SR. Therapeutic Approaches for Clostridium difficile Infections. Current Protocols in Microbiology 2013;30. [DOI: 10.1002/9780471729259.mc09a03s30] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
63 Johnson S, Gerding DN, Louie TJ, Ruiz NM, Gorbach SL. Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 2012;56:4043-5. [PMID: 22615287 DOI: 10.1128/AAC.00605-12] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
64 Broecker F, Klumpp J, Moelling K. Long-term microbiota and virome in a Zürich patient after fecal transplantation against Clostridium difficile infection. Ann N Y Acad Sci 2016;1372:29-41. [PMID: 27286042 DOI: 10.1111/nyas.13100] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
65 Mir SA, Kellermayer R. Clostridium difficile infection in newly diagnosed pediatric inflammatory bowel disease in the mid-southern United States. J Pediatr Gastroenterol Nutr. 2013;57:487-488. [PMID: 23783013 DOI: 10.1097/mpg.0b013e3182a027c5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
66 Carroll KC, Buchan BW, Tan S, Stamper PD, Riebe KM, Pancholi P, Kelly C, Rao A, Fader R, Cavagnolo R. Multicenter evaluation of the Verigene Clostridium difficile nucleic acid assay. J Clin Microbiol. 2013;51:4120-4125. [PMID: 24088862 DOI: 10.1128/jcm.01690-13] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 3.1] [Reference Citation Analysis]
67 Smith AB, Soto Ocana J, Zackular JP. From Nursery to Nursing Home: Emerging Concepts in Clostridioides difficile Pathogenesis. Infect Immun 2020;88:e00934-19. [PMID: 32122939 DOI: 10.1128/IAI.00934-19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
68 Burnham CA, Carroll KC. Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories. Clin Microbiol Rev. 2013;26:604-630. [PMID: 23824374 DOI: 10.1128/cmr.00016-13] [Cited by in Crossref: 248] [Cited by in F6Publishing: 120] [Article Influence: 31.0] [Reference Citation Analysis]
69 Hirsch BE, Saraiya N, Poeth K, Schwartz RM, Epstein ME, Honig G. Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection. BMC Infect Dis 2015;15:191. [PMID: 25885020 DOI: 10.1186/s12879-015-0930-z] [Cited by in Crossref: 97] [Cited by in F6Publishing: 88] [Article Influence: 13.9] [Reference Citation Analysis]
70 Gil F, Lagos-moraga S, Calderón-romero P, Pizarro-guajardo M, Paredes-sabja D. Updates on Clostridium difficile spore biology. Anaerobe 2017;45:3-9. [DOI: 10.1016/j.anaerobe.2017.02.018] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
71 Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA. 2015;313:398-408. [PMID: 25626036 DOI: 10.1001/jama.2014.17103] [Cited by in Crossref: 274] [Cited by in F6Publishing: 237] [Article Influence: 39.1] [Reference Citation Analysis]
72 Ghose C, Eugenis I, Edwards AN, Sun X, McBride SM, Ho DD. Immunogenicity and protective efficacy of Clostridium difficile spore proteins. Anaerobe 2016;37:85-95. [PMID: 26688279 DOI: 10.1016/j.anaerobe.2015.12.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
73 McFarland LV, Ozen M, Dinleyici EC, Goh S. Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections. World J Gastroenterol 2016; 22(11): 3078-3104 [PMID: 27003987 DOI: 10.3748/wjg.v22.i11.3078] [Cited by in CrossRef: 67] [Cited by in F6Publishing: 51] [Article Influence: 11.2] [Reference Citation Analysis]
74 Ünal CM, Steinert M. Novel therapeutic strategies for Clostridium difficile infections. Expert Opin Ther Targets 2016;20:269-85. [PMID: 26565670 DOI: 10.1517/14728222.2016.1090428] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
75 Kelly CR, Ihunnah C, Fischer M, Khoruts A, Surawicz C, Afzali A, Aroniadis O, Barto A, Borody T, Giovanelli A, Gordon S, Gluck M, Hohmann EL, Kao D, Kao JY, McQuillen DP, Mellow M, Rank KM, Rao K, Ray A, Schwartz MA, Singh N, Stollman N, Suskind DL, Vindigni SM, Youngster I, Brandt L. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol. 2014;109:1065-1071. [PMID: 24890442 DOI: 10.1038/ajg.2014.133] [Cited by in Crossref: 378] [Cited by in F6Publishing: 338] [Article Influence: 47.3] [Reference Citation Analysis]
76 Chilton CH, Crowther GS, Freeman J, Todhunter SL, Nicholson S, Longshaw CM, Wilcox MH. Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure. Journal of Antimicrobial Chemotherapy 2014;69:451-62. [DOI: 10.1093/jac/dkt347] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
77 Seril DN, Ashburn JH, Lian L, Shen B. Risk factors and management of refractory or recurrent clostridium difficile infection in ileal pouch patients. Inflamm Bowel Dis. 2014;20:2226-2233. [PMID: 25222656 DOI: 10.1097/mib.0000000000000205] [Cited by in Crossref: 27] [Cited by in F6Publishing: 11] [Article Influence: 3.9] [Reference Citation Analysis]
78 Rhea S, Hilscher R, Rineer JI, Munoz B, Jones K, Endres-Dighe SM, DiBiase LM, Sickbert-Bennett EE, Weber DJ, MacFarquhar JK, Dubendris H, Bobashev G. Creation of a Geospatially Explicit, Agent-based Model of a Regional Healthcare Network with Application to Clostridioides difficile Infection. Health Secur 2019;17:276-90. [PMID: 31433281 DOI: 10.1089/hs.2019.0021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
79 Rao K, Erb-Downward JR, Walk ST, Micic D, Falkowski N, Santhosh K, Mogle JA, Ring C, Young VB, Huffnagle GB, Aronoff DM. The systemic inflammatory response to Clostridium difficile infection. PLoS One 2014;9:e92578. [PMID: 24643077 DOI: 10.1371/journal.pone.0092578] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
80 Knight DR, Elliott B, Chang BJ, Perkins TT, Riley TV. Diversity and Evolution in the Genome of Clostridium difficile. Clin Microbiol Rev 2015;28:721-41. [PMID: 26085550 DOI: 10.1128/CMR.00127-14] [Cited by in Crossref: 146] [Cited by in F6Publishing: 84] [Article Influence: 20.9] [Reference Citation Analysis]
81 Dembek M, Barquist L, Boinett CJ, Cain AK, Mayho M, Lawley TD, Fairweather NF, Fagan RP. High-throughput analysis of gene essentiality and sporulation in Clostridium difficile. mBio 2015;6:e02383. [PMID: 25714712 DOI: 10.1128/mBio.02383-14] [Cited by in Crossref: 93] [Cited by in F6Publishing: 64] [Article Influence: 13.3] [Reference Citation Analysis]
82 Ofosu A. Clostridium difficile infection: a review of current and emerging therapies. Ann Gastroenterol 2016;29:147-54. [PMID: 27065726 DOI: 10.20524/aog.2016.0006] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 10.2] [Reference Citation Analysis]
83 Shaughnessy MK, Bobr A, Kuskowski MA, Johnston BD, Sadowsky MJ, Khoruts A, Johnson JR. Environmental Contamination in Households of Patients with Recurrent Clostridium difficile Infection. Appl Environ Microbiol 2016;82:2686-92. [PMID: 26921425 DOI: 10.1128/AEM.03888-15] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
84 Normington C, Moura IB, Bryant JA, Ewin DJ, Clark EV, Kettle MJ, Harris HC, Spittal W, Davis G, Henn MR, Ford CB, Wilcox MH, Buckley AM. Biofilms harbour Clostridioides difficile, serving as a reservoir for recurrent infection. NPJ Biofilms Microbiomes 2021;7:16. [PMID: 33547298 DOI: 10.1038/s41522-021-00184-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
85 Marsh JW, Arora R, Schlackman JL, Shutt KA, Curry SR, Harrison LH. Association of relapse of Clostridium difficile disease with BI/NAP1/027. J Clin Microbiol 2012;50:4078-82. [PMID: 23052318 DOI: 10.1128/JCM.02291-12] [Cited by in Crossref: 90] [Cited by in F6Publishing: 52] [Article Influence: 9.0] [Reference Citation Analysis]
86 Alam MZ, Wu X, Mascio C, Chesnel L, Hurdle JG. Mode of action and bactericidal properties of surotomycin against growing and nongrowing Clostridium difficile. Antimicrob Agents Chemother 2015;59:5165-70. [PMID: 26055381 DOI: 10.1128/AAC.01087-15] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
87 Kraus CN, Lyerly MW, Carman RJ. Ambush of Clostridium difficile spores by ramoplanin: activity in an in vitro model. Antimicrob Agents Chemother 2015;59:2525-30. [PMID: 25691641 DOI: 10.1128/AAC.04853-14] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
88 Varier RU, Biltaji E, Smith KJ, Roberts MS, Kyle Jensen M, LaFleur J, Nelson RE. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection. Infect Control Hosp Epidemiol 2015;36:438-44. [PMID: 25782899 DOI: 10.1017/ice.2014.80] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 7.7] [Reference Citation Analysis]
89 Kim J, Seo MR, Kang JO, Kim Y, Hong SP, Pai H. Clinical characteristics of relapses and re-infections in Clostridium difficile infection. Clin Microbiol Infect 2014;20:1198-204. [PMID: 24894547 DOI: 10.1111/1469-0691.12704] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]